TEM Tempus AI, Inc. - Class A Common Stock
$45,24
Preço · Mai 20, 2026
Fundamentais a partir de Mai 5, 2026
Intervalo 52 Semanas
$42–$104
6% of range
Classificação do Analista
BUY
24 analysts
Preço-Alvo
$67
+49% upside
P/E (TTM)
-41.9
ROE
-61.2%
Margem de Lucro Líquido
-19.3%
TEM Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$45.23
Capitalização de Mercado
—
P/E (TTM)
-41.9
EPS (TTM)
$-1.41
Receita (TTM)
$1.27B
Rendimento div.
—
ROE
-61.2%
Dívida/Capital
—
Intervalo 52 Semanas
$42 – $104
TEM Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$1.27B
2022-12-31
→
2025-12-31
EPS
$-1.41
2022-12-31
→
2025-12-31
Fluxo de caixa livre
$-239M
2024-12-31
→
2025-12-31
Margens
-19.3%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
TEM
Mediana de Pares
P/E (TTM)
-41.9
37.6
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
TEM
Mediana de Pares
Operating Margin (Margem Operacional)
-19.9%
—
Net Profit Margin (Margem de Lucro Líquido)
-19.3%
11.7%
ROA
-15.3%
4.7%
ROE
-61.2%
7.4%
ROIC
-42.3%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
TEM
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
3.1
2.5
Quick Ratio (Índice de Liquidez Seca)
2.5
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
TEM
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
83.4%
—
Revenue CAGR 3Y (CAGR Receita 3A)
58.3%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
TEM
Mediana de Pares
Payout Ratio (Índice de Pagamento)
0.00%
—
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
Dividend Yield
—
Índice de Pagamento
0.00%
CAGR Dividendos 5 anos
—
TEM Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
24 analistas
- Compra forte 6 25,0%
- Compra 9 37,5%
- Manter 8 33,3%
- Venda 0 0,0%
- Venda forte 1 4,2%
Preço-alvo de 12 meses
15 analistas · 2026-05-20
Mediana
$64.00
Agora
$45.23
Mín
$35.00
Máx
$100.00
Alvo mediano
$64.00
+41,5%
Alvo médio
$67.20
+48,6%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.04%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 31 de Março de 2026 | $-0.13 | $-0.19 | 0.06% |
| 31 de Dezembro de 2025 | $-0.04 | $-0.04 | 0.00% |
| 30 de Setembro de 2025 | $-0.11 | $-0.17 | 0.06% |
| 30 de Junho de 2025 | $-0.22 | $-0.24 | 0.02% |
| 31 de Março de 2025 | $-0.24 | $-0.29 | 0.05% |
Comparação com pares Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| BIO | — | — | — | — | — | — |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| BRKR | $7.17B | -314.1 | 2.1% | -0.25% | -0.40% | 45.9% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $1.27B | $693M | $532M | $321M | |
| R&D Expense | $173M | $149M | $90M | $83M | |
| SG&A Expense | $732M | $755M | $297M | $233M | |
| Operating Expenses | $1.52B | $1.38B | $728M | $586M | |
| Operating Income | $-253M | $-691M | $-196M | $-265M | |
| Interest Income | $13M | $11M | $8M | $3M | |
| Other Non-op | $31M | $32M | $22M | $-5M | |
| Pretax Income | $-291M | $-701M | $-214M | $-289M | |
| Income Tax | $-52M | $266.0K | $288.0K | $66.0K | |
| Net Income | $-245M | $-706M | $-214M | $-290M | |
| EPS (Basic) | $-1.41 | $-6.23 | $-4.20 | $-5.30 | |
| EPS (Diluted) | $-1.41 | $-6.23 | $-4.20 | $-5.30 | |
| Shares (Basic) | 174,264 | 119,849 | 63,306 | 63,306 | |
| Shares (Diluted) | 174,264 | 119,849 | 63,306 | 63,032 | |
| EBITDA | $-253M | $-691M | · | · |
Balanço Patrimonial 22
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $605M | $341M | $166M | $303M | |
| Receivables | $311M | $155M | $94M | · | |
| Inventory | $52M | $38M | $29M | · | |
| Prepaid Expense | $40M | $26M | $17M | · | |
| Current Assets | $1.17B | $668M | $350M | · | |
| PP&E (Net) | $89M | $58M | $62M | · | |
| PP&E (Gross) | $227M | $163M | $141M | · | |
| Accum. Depreciation | $137M | $105M | $79M | · | |
| Goodwill | $470M | $73M | $73M | $53M | |
| Intangibles | $349M | $12M | $22M | · | |
| Total Assets | $2.27B | $926M | $564M | · | |
| Accounts Payable | $82M | $54M | $54M | · | |
| Accrued Liabilities | $155M | $130M | $83M | · | |
| Current Liabilities | $372M | $291M | $233M | · | |
| Capital Leases | $74M | $26M | $32M | · | |
| Other Non-current Liabilities | $57M | $16M | $20M | · | |
| Total Liabilities | $1.78B | $870M | $841M | · | |
| Retained Earnings | $-2.40B | $-2.15B | $-1.40B | · | |
| Treasury Stock | $7M | $4M | $4M | · | |
| AOCI | $902.0K | $94.0K | $5.0K | · | |
| Stockholders' Equity | $491M | $56M | $-1.38B | $-1.13B | |
| Liabilities + Equity | $2.27B | $926M | $564M | · |
Fluxo de Caixa 11
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Stock-based Comp | $125M | $534M | $0 | $0 | |
| Deferred Tax | $-53M | $0 | $0 | · | |
| Operating Cash Flow | $-218M | $-189M | $-214M | $-168M | |
| CapEx | $21M | $22M | $35M | $18M | |
| Investing Cash Flow | $-398M | $-130M | $-40M | $-58M | |
| Net Debt Issued | $-277M | · | · | · | |
| Dividends Paid | $0 | $6M | $6M | $6M | |
| Financing Cash Flow | $884M | $494M | $118M | $251M | |
| Net Change in Cash | $268M | $175M | $-137M | $25M | |
| Taxes Paid | $654.0K | $206.0K | $161.0K | $6.0K | |
| Free Cash Flow | $-239M | $-211M | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Margin | -19.9% | -99.7% | · | · | |
| Net Margin | -19.3% | -101.8% | · | · | |
| Pretax Margin | -22.9% | -101.1% | · | · | |
| EBITDA Margin | -19.9% | -99.7% | · | · | |
| ROA | -15.3% | -94.7% | · | · | |
| ROE | -61.2% | -1282.5% | · | · | |
| ROIC | -42.3% | -1227.1% | · | · |
Liquidez e Solvência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 3.1 | 2.3 | · | · | |
| Quick Ratio | 2.5 | 1.7 | · | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.9 | · | · | |
| Receivables Turnover | 5.5 | 5.6 | · | · |
Taxas de Crescimento 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | 83.4% | 30.4% | 65.8% | · | |
| Revenue CAGR 3Y | 58.3% | · | · | · |
Avaliação (TTM) 6
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $1.27B | $693M | · | · | |
| Net Income TTM | $-245M | $-706M | · | · | |
| P/E | -41.9 | -5.4 | · | · | |
| Earnings Yield | -2.4% | -18.4% | · | · | |
| Payout Ratio | 0.00% | -0.80% | · | · | |
| Annual Payout | $0 | $6M | · | · |
Demonstração de Resultados 15
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $348M | $367M | $334M | $315M | $256M | $201M | $181M | $166M | $146M | $148M | $136M | |
| R&D Expense | $48M | $50M | $45M | $42M | $36M | $30M | $27M | $68M | $24M | $24M | $23M | |
| SG&A Expense | $213M | $209M | $188M | $181M | $155M | $111M | $101M | $463M | $80M | $85M | $71M | |
| Operating Expenses | $433M | $429M | $395M | $376M | $324M | $251M | $235M | $699M | $199M | $200M | $181M | |
| Operating Income | $-85M | $-61M | $-61M | $-62M | $-69M | $-51M | $-54M | $-533M | $-53M | $-52M | $-45M | |
| Interest Income | $4M | $5M | $5M | $1M | $2M | $4M | $5M | $2M | $1M | $2M | $1M | |
| Other Non-op | $-28M | $15M | $3M | $42M | $-27M | $50M | $-12M | $-7M | $749.0K | $14M | $2M | |
| Pretax Income | $-123M | $-57M | $-81M | $-41M | $-112M | $-10M | $-74M | $-552M | $-65M | $-50M | $-53M | |
| Income Tax | $-62.0K | $-6M | $276.0K | $212.0K | $-46M | $122.0K | $38.0K | $95.0K | $11.0K | · | · | |
| Net Income | $-126M | $-54M | $-80M | $-43M | $-68M | $-13M | $-76M | $-552M | $-65M | $-50M | $-53M | |
| EPS (Basic) | $-0.70 | $-0.30 | $-0.46 | $-0.25 | $-0.40 | $2.56 | $-0.46 | $-6.86 | $-1.47 | $-1.06 | $-1.03 | |
| EPS (Diluted) | $-0.71 | $-0.30 | $-0.46 | $-0.25 | $-0.40 | $2.56 | $-0.46 | $-6.86 | $-1.47 | $-1.06 | $-1.03 | |
| Shares (Basic) | 178,880 | -344,568 | 174,945 | 173,381 | 170,506 | -191,518 | 165,612 | 82,325 | 63,430 | 39 | 63,286 | |
| Shares (Diluted) | 178,964 | -344,568 | 174,945 | 173,381 | 170,506 | -191,518 | 165,612 | 82,325 | 63,430 | 39 | 63,286 | |
| EBITDA | $-85M | · | $-61M | $-62M | $-69M | · | $-54M | $-533M | · | · | · |
Balanço Patrimonial 22
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $521M | $605M | $656M | $186M | $152M | $341M | $388M | $479M | · | $166M | · | |
| Receivables | $309M | $311M | $284M | $266M | $263M | $155M | $146M | $118M | · | · | · | |
| Inventory | $52M | $52M | $55M | $48M | $50M | $38M | $36M | $33M | · | · | · | |
| Prepaid Expense | $43M | $40M | $43M | $36M | $42M | $26M | $31M | $30M | · | · | · | |
| Current Assets | $1.05B | $1.17B | $1.15B | $644M | $574M | $668M | $679M | $671M | · | · | · | |
| PP&E (Net) | $89M | $89M | $91M | $93M | $94M | $58M | $59M | $61M | · | · | · | |
| PP&E (Gross) | $233M | $227M | $220M | $214M | $207M | $163M | $158M | $152M | · | · | · | |
| Accum. Depreciation | $144M | $137M | $130M | $122M | $113M | $105M | $99M | $92M | · | · | · | |
| Goodwill | $470M | $470M | $465M | $326M | $326M | $73M | $73M | $73M | · | $73M | · | |
| Intangibles | $331M | $355M | $373M | $388M | $400M | $12M | $14M | $16M | · | · | · | |
| Total Assets | $2.14B | $2.27B | $2.28B | $1.63B | $1.54B | $926M | $972M | $865M | · | · | · | |
| Accounts Payable | $41M | $82M | $60M | $79M | $89M | $54M | $49M | $29M | · | · | · | |
| Accrued Liabilities | $161M | $155M | $161M | $166M | $129M | $130M | $102M | $85M | · | · | · | |
| Current Liabilities | $318M | $372M | $350M | $418M | $336M | $291M | $253M | $182M | · | · | · | |
| Capital Leases | $73M | $74M | $78M | $46M | $48M | $26M | $27M | $27M | · | · | · | |
| Other Non-current Liabilities | $54M | $57M | $59M | $10M | $10M | $16M | $15M | $17M | · | · | · | |
| Total Liabilities | $1.72B | $1.78B | $1.77B | $1.32B | $1.22B | $870M | $918M | $766M | · | · | · | |
| Retained Earnings | $-2.52B | $-2.40B | $-2.34B | $-2.26B | $-2.22B | $-2.15B | $-2.14B | $-2.06B | · | · | · | |
| Treasury Stock | $7M | $7M | $4M | $4M | $4M | $4M | $4M | $4M | · | · | · | |
| AOCI | $-908.0K | $902.0K | $6M | $8M | $5M | $94.0K | $10M | $-94.0K | · | · | · | |
| Stockholders' Equity | $416M | $491M | $508M | $310M | $326M | $56M | $54M | $98M | · | $-1.38B | · | |
| Liabilities + Equity | $2.14B | $2.27B | $2.28B | $1.63B | $1.54B | $926M | $972M | $865M | · | · | · |
Fluxo de Caixa 10
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $53M | $45M | $34M | $22M | $23M | $25M | $21M | $488M | $0 | $0 | $0 | |
| Deferred Tax | $0 | $-6M | $0 | $0 | $-46M | $0 | $0 | $0 | $0 | · | · | |
| Operating Cash Flow | $-73M | $-37M | $-120M | $44M | $-106M | $-39M | $49M | $-97M | $-101M | $-40M | $-53M | |
| CapEx | $8M | $5M | $7M | $8M | $2M | $8M | $43.0K | $8M | $6M | $3M | $16M | |
| Investing Cash Flow | $-10M | $-11M | $-2M | $-10M | $-376M | $-8M | $-131M | $-8M | $17M | $-6M | $-16M | |
| Dividends Paid | · | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $0 | |
| Financing Cash Flow | $-271.0K | $-4M | $595M | $0 | $293M | $-179.0K | $-8M | $504M | $-1M | $79M | $-519.0K | |
| Net Change in Cash | $-84M | $-51M | $472M | $35M | $-189M | $-47M | $-91M | $399M | $-86M | $33M | $-70M | |
| Taxes Paid | $-56.0K | $81.0K | $437.0K | $136.0K | $0 | $79.0K | $38.0K | $89.0K | $0 | $60.0K | $60.0K | |
| Free Cash Flow | $-81M | · | · | · | $-108M | · | · | · | · | · | · |
Lucratividade 7
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -24.3% | · | -18.2% | -19.6% | -26.9% | · | -29.6% | -321.4% | · | · | · | |
| Net Margin | -36.2% | · | -23.9% | -13.6% | -26.6% | · | -41.9% | -332.7% | · | · | · | |
| Pretax Margin | -35.3% | · | -24.3% | -12.9% | -43.9% | · | -41.0% | -332.7% | · | · | · | |
| EBITDA Margin | -24.3% | · | -18.2% | -19.6% | -26.9% | · | -29.6% | -321.4% | · | · | · | |
| ROA | -6.9% | · | -4.9% | -3.4% | -8.8% | · | -15.6% | -127.7% | · | · | · | |
| ROE | -33.9% | · | -28.5% | -21.0% | -41.7% | · | -282.3% | -1124.1% | · | · | · | |
| ROIC | -20.3% | · | -12.0% | -20.1% | -12.4% | · | · | · | · | · | · |
Liquidez e Solvência 2
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | · | 3.3 | 1.5 | 1.7 | · | 2.7 | 3.7 | · | · | · | |
| Quick Ratio | 2.6 | · | 2.7 | 1.1 | 1.2 | · | 2.1 | 3.3 | · | · | · |
Eficiência 2
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.4 | 0.4 | · | · | · | |
| Receivables Turnover | 1.2 | · | 1.6 | 1.6 | 1.9 | · | 2.5 | 2.8 | · | · | · |
Avaliação (TTM) 4
| Métrica | Tendência | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.25B | · | $1.09B | $917M | $748M | · | $629M | $580M | · | · | · | |
| Net Income TTM | $-317M | · | $-267M | $-739M | $-761M | · | $-746M | $-726M | · | · | · | |
| P/E | -24.8 | · | -51.4 | -8.0 | -5.2 | · | -5.8 | -3.4 | · | · | · | |
| Earnings Yield | -4.0% | · | -1.9% | -12.5% | -19.1% | · | -17.3% | -29.8% | · | · | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Receita | $1.27B | $693M | $532M | $321M |
| Margem Operacional % | -19.9% | -99.7% | — | — |
| Lucro líquido | $-245M | $-706M | $-214M | $-290M |
| EPS Diluído | $-1.41 | $-6.23 | $-4.20 | $-5.30 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Índice de liquidez corrente | 3.1 | 2.3 | — | — |
| Índice de Liquidez Seca | 2.5 | 1.7 | — | — |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Fluxo de caixa livre | $-239M | $-211M | — | — |
Últimas notícias Notícias recentes mencionando esta empresa
- Como a Ação Desvalorizada da Tempus AI Oferece um Bilhete de Loteria para Traders Aqui
- Aqui está o que a TD Cowen pensa sobre as ações da Tempus AI Inc (TEM)
- Fluxo de ETF Notável Detectado - ARKK, CRSP, TEM, HOOD
- Gilead (GILD), Tempus AI (TEM) Expandem Colaboração Multianual de P&D em Oncologia
- Tempus AI Inc. (TEM) é recomendada como compra em meio ao foco em oportunidades de saúde
- H.C. Wainwright Eleva o Preço-Alvo da Tempus AI (TEM) para $95
- Talisman conclui trabalho de amostragem no Projeto de Cobre-Prata de Fougnar
- Tempus AI (TEM) é a Melhor Ação de Saúde com IA no Portfólio de Cathie Wood?
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.